biostudies-literatureShah MVPaul Calabresi Program in Clinical/Translational Research at Mayo Clinic1013-1022https://www.ebi.ac.uk/biostudies/studies/S-EPMC9541522biostudies-literatureUnknown97(8)Therapy-related myeloid neoplasms (t-MN) are aggressive malignancies in need of effective therapies. The BCL-2 inhibitor venetoclax represents a paradigm shift in the treatment of acute myeloid leukemia. However, the effectiveness of venetoclax has not been studied in a large cohort of t-MN. We retrospectively analyzed 378 t-MN patients, of which 96 (25.4%, 47 therapy-related acute myeloid leukemia, 1 therapy-related chronic myelomonocytic leukemia, 48 therapy-related myelodysplastic syndrome) received venetoclax. Median interval from t-MN to venetoclax initiation was 2.9 (Interquartile range [IQR] 0.7-12) months, and patients received a median of 3 (IQR 1-4) cycles. The composite complete remission (CRc) rate, median progression-free survival (PFS), and overall survival (OS) were 39.1%, 4American journal of hematologyOutcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.PMC9541522K12CA090628Hiwase DAlkhateeb HBBegna KHChhetri RGangat NAl-Kali ABaranwal AHe RShah MVTiong ISGreipp PTKok CHDholakia RWei AHPatnaik MMfalseOutcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.Therapy-related myeloid neoplasms (t-MN) are aggressive malignancies in need of effective therapies. The BCL-2 inhibitor venetoclax represents a paradigm shift in the treatment of acute myeloid leukemia. However, the effectiveness of venetoclax has not been studied in a large cohort of t-MN. We retrospectively analyzed 378 t-MN patients, of which 96 (25.4%, 47 therapy-related acute myeloid leukemia, 1 therapy-related chronic myelomonocytic leukemia, 48 therapy-related myelodysplastic syndrome) received venetoclax. Median interval from t-MN to venetoclax initiation was 2.9 (Interquartile range [IQR] 0.7-12) months, and patients received a median of 3 (IQR 1-4) cycles. The composite complete remission (CRc) rate, median progression-free survival (PFS), and overall survival (OS) were 39.1%, 42022-01-01T00:00:00Z2022 Aug2025-04-22T01:53:30.151Z2025-04-05T20:12:10.476ZS-EPMC95415223556006110.1002/ajh.26589